Abbott Introduces Generative AI Technology, Redefining Meal Decisions for People Living With Diabetes
Published: 08 Jan 2026
Author: Precedence Research
Abbott has recently announced an innovative AI technology, Libre Assist, a generative artificial intelligence-based tool that assists people with diabetes in making more confident and informed food decisions. Introduced at CES 2026, Libre Assist is a direct integration of the Libre by Abbott mobile application. This allows the Abbott continuous glucose monitoring (CGM) ecosystem to monitor, but also to predictively support decisions. This characteristic represents a rising change in digital health, which is more proactive and assists users in predicting health results as opposed to merely responding to them.
The Libre Assist is a device used to determine how a meal affects the level of glucose prior to its consumption. Users can input food information either by typing or attaching a photograph, and a color-coded determination will be displayed. This further shows the estimated impact such a meal will have on blood glucose levels. The Artificial Intelligence technology, available in the Insights section of the app, thus helps decrease uncertainty regarding everyday food choices, which is one of the most problematic areas of diabetes self-management.
The fundamental component of Libre Assist is a two-layer technical design. This integrates AI prediction, which is generative and sensor-based. The system pre-consumes food and uses GenAI models to interpret food composition, food ingredients, and approximate nutritional effect on the glucose level.
In addition to its technical design, Libre Assist fills an existing gap in applications of diabetes care. Libre Assist is free of charge and can be found in the Apple App Store and on the Google Play Store. They support Abbott's strategy to increase access to high-quality digital solutions in its existing ecosystem. Furthermore, Abbott is defining a novel template of how future generations of digital health solutions can be safely scaled to accommodate global groups of patients
Executive Statement
Marc Taub, Vice President, Technical Operations, Abbott Diabetes Care (CTO-level leadership)
“People with diabetes need more than food logs; they need insight at the moment decisions are made. Libre Assist was built to deliver predictive guidance supported by real-time CGM data, ensuring that AI-driven insights are not only intelligent but also physiologically validated and clinically relevant.”